Blinde, rangordnede vurderinger af både nekro- inflammatorisk aktivitet og fibrose ved baseline og ved uge 48 påviste, at patienter behandlet med 10 mg adefovirdipivoxil havde bedre nekro- inflammatoriske og fibrosescorer end placebokontrollerede patienter.
Blinded, ranked assessments of both necro- inflammatory activity and fibrosis at baseline and week 48, demonstrated that patients treated with 10 mg adefovir dipivoxil had improved necro-inflammatory and fibrosis scores relative to placebo- treated patients.